Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
NCT ID: NCT00135421
Last Updated: 2010-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
271 participants
INTERVENTIONAL
2005-11-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
NCT01369095
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
NCT00566202
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
NCT02191397
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
NCT01361555
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1
Pexacerfont
Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
A2
Escitalopram
Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
A3
Placebo
Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pexacerfont
Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
Escitalopram
Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Placebo
Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients whose current depressive episode is at least three months in duration at the Baseline Visit.
Exclusion Criteria
* Patients with treatment resistance to other antidepressants
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Apc Clinical Research Trials Nw, Pa
Springdale, Arkansas, United States
Pacific Clinical Research Medical Group
Orange, California, United States
Pacific Clinical Research Medical Group
Upland, California, United States
Front Range Clinical Research
Wheat Ridge, Colorado, United States
University Of Connecticut Health Center
Farmington, Connecticut, United States
University Of Florida
Gainesville, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Emory University
Atlanta, Georgia, United States
Cunningham Clinical Research, Llc
Edwardsville, Illinois, United States
Alexian Center For Psychiatric Research
Hoffman Estates, Illinois, United States
American Medical Research, Inc.
Oak Brook, Illinois, United States
Alpine Clinic
Lafayette, Indiana, United States
J. Gary Booker, Md
Shreveport, Louisiana, United States
Dupont Clinical Research
Rockville, Maryland, United States
Summit Research Network
Farmington Hills, Michigan, United States
Regions Hospital
Saint Paul, Minnesota, United States
Albuquerque Neuroscience, Inc.
Albuquerque, New Mexico, United States
Social Psychiatry Research Institute
Brooklyn, New York, United States
Neurobehavioral Research, Inc.
Cedarhurst, New York, United States
Bioscience Research, Llc
New York, New York, United States
Social Psychiatry Research Institute
New York, New York, United States
Behavioral Medical Research Of Staten Island
Staten Island, New York, United States
University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina, United States
Richard H. Weisler, Md
Raleigh, North Carolina, United States
Community Research
Cincinnati, Ohio, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Oregon Center For Clinical Investigations, Inc. (Occi, Inc)
Portland, Oregon, United States
Summit Research Network
Portland, Oregon, United States
Suburban Research Associates
Media, Pennsylvania, United States
Usc School Of Medicine
Columbia, South Carolina, United States
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States
Futuresearch Trials
Austin, Texas, United States
Claghorn-Lesem Research Clinic
Bellaire, Texas, United States
Insite Clinical Research
DeSoto, Texas, United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, United States
Croft, Harry A.
San Antonio, Texas, United States
Radiant Research, Salt Lake City
Salt Lake City, Utah, United States
University Of Utah School Of Medicine
Salt Lake City, Utah, United States
Psychiatric Alliance Of The Blue Ridge
Charlottesville, Virginia, United States
Dominion Clinical Research
Midlothian, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Summit Research Network (Seattle), Inc.
Seattle, Washington, United States
Northbrooke Research Center
Brown Deer, Wisconsin, United States
Dean Foundation For Health Research & Education
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN148-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.